Fortress Biotech Gains FDA Approval for ZYCUBO® and Closes $205M PRV Sale in Q1 2026

Fortress Biotech's Cyprium Therapeutics subsidiary converted an FDA approval into $205 million in liquidity during Q1 2026, demonstrating how the Rare Pediatric Disease Priority Review Voucher mechanism can function as a discrete financing instrument within a small biotech's commercialization model. For plant heads and QA directors watching rare disease pipelines, the ZYCUBO® pathway illustrates the full arc from regulatory submission to PRV monetization within a single quarter.

The FDA approved ZYCUBO® (copper histidinate) for Menkes disease in pediatric patients in January 2026. A PRV was issued at approval and transferred to Cyprium under its agreement with Sentynl Therapeutics. Cyprium closed the PRV sale in March 2026 for gross proceeds of $205 million, then redeemed all outstanding shares of its 9.375% Perpetual Preferred Stock. Cyprium retains eligibility for tiered royalties on ZYCUBO® net sales and up to approximately $128 million in aggregate sales milestones from Sentynl, preserving downstream revenue exposure without carrying commercial manufacturing obligations directly.

The PRV proceeds supported balance sheet restructuring: Fortress reduced its outstanding principal with Oaktree to $15.0 million. Consolidated net income attributable to common stockholders for Q1 2026 reached $108.4 million, or $3.44 per share (basic), reflecting the PRV transaction's outsized contribution to the period. For QA and regulatory leads benchmarking rare disease program economics, the Cyprium case offers a concrete data point on PRV valuation at the $205 million level in early 2026.

Separately, Fortress's subsidiary Checkpoint was acquired by Sun Pharmaceutical Industries in May 2025. The transaction delivered approximately $28 million upfront, a contingent value right of up to $4.8 million, and a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl), which received FDA approval in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma and launched commercially in January 2026. The royalty structure positions Fortress to capture revenue from Sun Pharma's commercial and manufacturing infrastructure without maintaining its own commercial-scale operations for the asset.

On the pipeline side, Avenue's acquisition of ATX-04 from Duke University adds a clinically validated program targeting Pompe disease. AstraZeneca has also filed regulatory submissions in the EU and Japan for anselamimab (formerly CAEL-101), a partnered asset that carries potential approval and sales milestones for Fortress if those dossiers advance.

Cyprium's tiered royalty entitlement and the $128 million in remaining sales milestones from Sentynl represent the next measurable checkpoints against which Fortress's rare disease commercialization model will be assessed.

Source: Fortress Biotech, Inc. via GlobeNewswire, May 14, 2026.